- Immatics (NASDAQ: IMTX) to present IMA203 TCR T-cell therapy data at the 2025 ASCO Annual Meeting.
- Oral presentation will include updated data from the Phase 1b trial in metastatic melanoma patients.
- SUPRAME Phase 3 trial poster presentation to feature ongoing research in cutaneous melanoma patients.
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, has announced its participation in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The company will present critical updates on its lead cell therapy candidate, IMA203 TCR T-cell therapy, which targets PRAME, a protein prominently expressed in multiple solid tumors.
The presentations will cover significant advancements, including an oral presentation detailing updated data from the Phase 1b trial of IMA203. This includes extended follow-up results in metastatic melanoma patients and new data on uveal melanoma patients since the last update in October 2024.
Additionally, Immatics will also present a trial-in-progress poster for SUPRAME, a Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have previously undergone treatment with a checkpoint inhibitor.
Both the oral and poster presentations are part of the Developmental Therapeutics - Immunotherapy sessions, scheduled for May 31 and June 2, 2025. Full abstracts for these presentations will be available on the ASCO website on May 22, 2025, at 5:00 pm ET.
For further information, Immatics encourages interested parties to visit their official website and follow them on social media for regular updates on their research and development efforts in cancer immunotherapies.
